Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach.

Lee DJ, Zeidner JF.

Expert Opin Investig Drugs. 2019 Oct 15. doi: 10.1080/13543784.2019.1678583. [Epub ahead of print]

PMID:
31612739
2.

Trials and Tribulations of Corrected QT Interval Monitoring in Oncology: Rationale for a Practice-Changing Standardized Approach.

Muluneh B, Richardson DR, Hicks C, Jensen BC, Zeidner JF.

J Clin Oncol. 2019 Oct 20;37(30):2719-2721. doi: 10.1200/JCO.19.00922. Epub 2019 Jul 16. No abstract available.

PMID:
31310577
3.

Inversion 16 (inv(16)) acute myeloid leukemia (AML) following treatment with radiation, capecitabine, and temozolomide in a patient with metastatic neuroendocrine tumor (NET).

Joseph R, McRee AJ, Mathews S, Zeidner JF.

Leuk Lymphoma. 2019 May 23:1-5. doi: 10.1080/10428194.2019.1612060. [Epub ahead of print] No abstract available.

PMID:
31119961
4.

Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy.

Hu Q, Sun W, Wang J, Ruan H, Zhang X, Ye Y, Shen S, Wang C, Lu W, Cheng K, Dotti G, Zeidner JF, Wang J, Gu Z.

Nat Biomed Eng. 2018 Nov;2(11):831-840. doi: 10.1038/s41551-018-0310-2. Epub 2018 Oct 29.

PMID:
31015615
5.

Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy.

Knaus HA, Berglund S, Hackl H, Blackford AL, Zeidner JF, Montiel-Esparza R, Mukhopadhyay R, Vanura K, Blazar BR, Karp JE, Luznik L, Gojo I.

JCI Insight. 2018 Nov 2;3(21). pii: 120974. doi: 10.1172/jci.insight.120974.

6.

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).

Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE.

Leuk Res. 2018 Sep;72:92-95. doi: 10.1016/j.leukres.2018.08.005. Epub 2018 Aug 10. No abstract available.

PMID:
30118897
7.

Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after azacitidine treatment.

Yogarajah M, Montgomery N, Matson M, Blanchard L, Frank C, Gallagher S, Pepin K, Vaught L, Muluneh B, Foster MC, Zeidner JF.

Leuk Lymphoma. 2018 Dec;59(12):3010-3012. doi: 10.1080/10428194.2018.1459614. Epub 2018 May 11. No abstract available.

PMID:
29749763
8.

A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure.

Zeidan AM, Knaus HA, Robinson TM, Towlerton AMH, Warren EH, Zeidner JF, Blackford AL, Duffield AS, Rizzieri D, Frattini MG, Levy YM, Schroeder MA, Ferguson A, Sheldon KE, DeZern AE, Gojo I, Gore SD, Streicher H, Luznik L, Smith BD.

Clin Cancer Res. 2018 Aug 1;24(15):3519-3527. doi: 10.1158/1078-0432.CCR-17-3763. Epub 2018 May 1.

9.

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.

Swords RT, Coutre S, Maris MB, Zeidner JF, Foran JM, Cruz J, Erba HP, Berdeja JG, Tam W, Vardhanabhuti S, Pawlikowska-Dobler I, Faessel HM, Dash AB, Sedarati F, Dezube BJ, Faller DV, Savona MR.

Blood. 2018 Mar 29;131(13):1415-1424. doi: 10.1182/blood-2017-09-805895. Epub 2018 Jan 18.

10.

A Comparison of Clofarabine-based (GCLAC) and Cladribine-based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML.

Muluneh B, Buhlinger K, Deal AM, Zeidner JF, Foster MC, Jamieson KJ, Bates J, Van Deventer HW.

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e13-e18. doi: 10.1016/j.clml.2017.09.016. Epub 2017 Sep 22.

PMID:
29100976
11.

Association of acute myeloid leukemia's most immature phenotype with risk groups and outcomes.

Gerber JM, Zeidner JF, Morse S, Blackford AL, Perkins B, Yanagisawa B, Zhang H, Morsberger L, Karp J, Ning Y, Gocke CD, Rosner GL, Smith BD, Jones RJ.

Haematologica. 2016 May;101(5):607-16. doi: 10.3324/haematol.2015.135194. Epub 2016 Jan 27.

12.

Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute.

Zeidner JF, Karp JE, Blackford AL, Foster MC, Dees EC, Smith G, Ivy SP, Harris P.

J Natl Cancer Inst. 2015 Nov 9;108(3). doi: 10.1093/jnci/djv335. Print 2016 Mar.

13.

Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.

Zeidner JF, Karp JE.

Leuk Res. 2015 Dec;39(12):1312-8. doi: 10.1016/j.leukres.2015.10.010. Epub 2015 Oct 19. Review.

PMID:
26521988
14.

Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.

Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE.

Haematologica. 2015 Sep;100(9):1172-9. doi: 10.3324/haematol.2015.125849. Epub 2015 May 28.

15.

Optimizing the management of relapsed chronic myeloid leukemia post-allogeneic bone marrow transplant.

Zeidner JF, Smith BD.

Leuk Lymphoma. 2015;56(10):3001-2. doi: 10.3109/10428194.2015.1032969. Epub 2015 Jun 19. No abstract available.

PMID:
25804770
16.

Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML).

Zeidner JF, Foster MC.

Curr Drug Targets. 2017;18(3):304-314. doi: 10.2174/1389450116666150304104315. Review.

PMID:
25738295
17.

Lenalidomide-associated hemolytic anemia.

Lim MY, Raval JS, Richards KL, Zeidner JF, Foster MC.

Leuk Lymphoma. 2015;56(9):2717-9. doi: 10.3109/10428194.2014.1003558. Epub 2015 Mar 2. No abstract available.

PMID:
25644743
18.

Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-α (IFN) in newly diagnosed chronic myeloid leukemia (CML).

Zeidner JF, Gladstone DE, Zahurak M, Matsui WH, Gocke C, Jones RJ, Smith BD.

Leuk Res. 2014 Aug;38(8):886-90. doi: 10.1016/j.leukres.2014.05.012. Epub 2014 May 29.

19.

Reason for CPXcitement in AML.

Zeidner JF, Karp JE.

Blood. 2014 May 22;123(21):3211-2. doi: 10.1182/blood-2014-04-568725. No abstract available.

PMID:
24855187
20.

The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions?

Zeidner JF, Zahurak M, Rosner GL, Gocke CD, Jones RJ, Smith BD.

Leuk Lymphoma. 2015 Jan;56(1):128-34. doi: 10.3109/10428194.2014.910868. Epub 2014 Jun 16.

21.

A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.

Zeidner JF, Karp JE, Blackford AL, Smith BD, Gojo I, Gore SD, Levis MJ, Carraway HE, Greer JM, Ivy SP, Pratz KW, McDevitt MA.

Haematologica. 2014 Apr;99(4):672-8. doi: 10.3324/haematol.2013.097246. Epub 2013 Dec 20.

22.

Painless jaundice.

Zeidner JF, Sydnor E.

Am J Med. 2010 Jul;123(7):601-3. doi: 10.1016/j.amjmed.2010.03.007. No abstract available.

PMID:
20609681
23.

The tissue's the issue.

Zeidner JF, Ostrin EJ, Sydnor E, Fine D, Sperati CJ.

Am J Med. 2010 May;123(5):420-2. doi: 10.1016/j.amjmed.2010.01.008. No abstract available.

PMID:
20399317
24.

Investigational antiplatelet drugs for the treatment and prevention of coronary artery disease.

Zeidner JF, Frishman WH, Lerner RG.

Cardiol Rev. 2008 Sep-Oct;16(5):250-9. doi: 10.1097/CRD.0b013e3181804336. Review.

PMID:
18708826

Supplemental Content

Loading ...
Support Center